Modulatory action of hesperitin on osteogenesis and osteoclastogenesis

• Grant number: 19/26508-7
• Support Opportunities: Scholarships in Brazil - Scientific Initiation
• Effective date (Start): February 01, 2020
• Effective date (End): July 31, 2021
• Field of knowledge: Health Sciences - Dentistry - Periodontology
• Principal Investigator: Denise Madalena Palomari Spolidorio
• Grantee: Maria Júlia Mancim Imbriani
• Host Institution: Faculdade de Odontologia (FOAr). Universidade Estadual Paulista (UNESP). Campus de Araraquara. Araraquara , SP, Brazil

Abstract

The use of bioactive and low cost drugs appears as a promising alternative. Hesperitin is a metabolite of hesperidin in the flavonone subgroup with effective therapeutic properties such as antioxidant, anti-inflammatory, anticancer, neuroprotective, analgesic and beneficial effects on bone metabolism. Considering the biological properties of hesperitin and aiming to identify compounds that may act in the treatment of inflammatory bone diseases, such as periodontal disease, the aim of the present in vitro study is to evaluate the effect of hesperitin on metabolism of bone tissue, verifying their influence on the differentiation and metabolism of osteoblasts and osteoclasts. Initially in objective 1: Will be determined non-cytotoxic concentrations of hesperitin on MC3T3 osteoblast cell culture as well as its action on cell proliferation, formation of mineralization nodules and expression of genes regulating bone metabolism. Following on objective 2: The influence of hesperitin on osteoclastogenesis in vitro will be evaluated by TRAP (Tartrate-Resistant Acid Phosphatase). Human osteoclast precursor cells derived from hematopoietic stem cells isolated from human bone marrow will be stimulated with RANKL and treated with non-cytotoxic doses of hesperitin. The numerical data obtained by applying the laboratory protocols will be subjected to specific statistical analysis using the GraphPad Prism 6 software, and all tests of this study will be applied with a significance level of 5% (p <0.05). (AU)